Heptares Expands Executive Management Team with Appointment of Daniel Grau as President
Company to advance pipeline in neurological and metabolic areas, while harnessing broader discovery platform through alliances
Heptares Therapeutics announced the appointment of Daniel Grau as President. Mr Grau, who has been a Senior Advisor to Heptares focused on business development and corporate strategy since 2010, is based in Boston, MA and will have broad responsibilities for corporate and commercial development, reporting to Chief Executive Officer Malcolm Weir. He joins Heptares as it enters a new stage of growth and value creation, building upon a transformative year of pipeline breakthroughs and corporate deals.
Focused on novel GPCR-targeted medicines, Heptares has assembled a rich pipeline of first- and best-in-class therapeutic agents for serious neurological (CNS) and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, anxiety, chronic insomnia and type II diabetes. In addition, Heptares has signed commercial partnerships with leading pharma companies such as Takeda, AstraZeneca, Shire and Novartis.
Mr. Grau is currently a member of the Product Advisory Board of Concert Pharmaceuticals, Inc. Previously he served as President and CEO of Cortria Corporation, Chief Operating Officer of CombinatoRx, Inc. (today Zalicus), and as a business consultant to Pharmacia Corporation (today Pfizer). He earned his BA from Davidson College and holds an MPhil from Yale University.
Other news from the department people
